Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 512

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 512
---
 unless the duration of a company is limited by its articles of association, a company may be dissolved at any time by way of liquidation, or, in the case of a merger with the Swiss Merger Act (Fusionsgesetz), based on a resolution of a shareholders’ meeting, which must be passed by a majority as provided by Swiss law or the relevant company’s articles of association, as the case may be. The articles of association do not limit the duration of NLS and provide that the majority required for the shareholders’ meeting to resolve on the liquidation of NLS is a Supermajority Vote. Dissolution and liquidation by court order is also possible if, among other things, (i) the company becomes bankrupt or (ii) shareholders holding at least 10% of the company’s share capital so request for important reasons. Under Swiss law, any surplus arising out of a liquidation (after settlement of all the claims of the company’s creditors) is distributed in proportion to the paid -upnominal value of shares held. This surplus is subject to Swiss federal withholding tax, except if paid out of reserves from qualifying capital contributions (Reserven aus Kapitaleinlagen). A dissolution and winding up of a Swiss company requires a Supermajority Vote. The articles of association may increase the voting thresholds required for such a resolution (but only by way of a resolution with the majority stipulated by law). 309 OTHER SHAREHOLDER COMMUNICATIONS Shareholders and interested parties may communicate with the NLS Board, any committee chairperson or the non -managementdirectors as a group by writing to the NLS Board or committee chairperson in care of NLS at . Following the Merger, such communications should be sent in care of NLS at , and its telephone number is . Each communication will be forwarded, depending on the subject matter, to the NLS Board, the appropriate committee chairperson or all non -managementdirectors. LEGAL MATTERS Certain legal matters concerning this proxy statement/prospectus will be passed upon for us by Sullivan & Worcester LLP, New York, New York. Certain legal matters with respect to Swiss law will be passed upon for us by Baker McKenzie Switzerland AG, Zurich, Switzerland. Certain legal matters with respect to Kadimastem and Israeli law will be passed upon for us by Pearl Cohen Zedek Latzer Baratz LLP. EXPERTS The financial statements of NLS Pharmaceutics Ltd. as of December31, 2023 and for each of the two years